Koninklijke Philips N.V. (PHIA) AI Stock Analysis

• Market Cap: €21.70B
• Dividend Yield: 3.73%
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): 24.6
• Beta (1Y): 0.92
• Revenue Growth: -0.81%
• EPS Growth: -54.90%
• Country: NL
• Employees: 67,247
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.60
• Shares Outstanding: 962,920,100
• 10 Day Avg. Volume: 1,198,930
• 30 Day Avg. Volume: 1,333,770
• PEG Ratio: -0.11
• Price to Book (P/B): 2.01
• Price to Sales (P/S): 1.24
• P/FCF Ratio: 24.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €26.23
• Price Target Upside: 14.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 1.52
• Revenue Forecast (FY): €17.85B

• Rating: 64 Neutral
• Price Target: €24.50 ▲(7.31% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is driven primarily by improving financial performance (profitability rebound and strong 2025 free cash flow), supported by a clear uptrend in technicals. These positives are tempered by historical earnings volatility and a mixed valuation profile (higher P/E despite a solid dividend yield).

Positive Factors

Free Cash Flow Strength

A durable improvement in free cash flow in 2025 (≈€0.9B, +242%) signals stronger internal cash generation after multiyear swings. Sustained FCF supports reinvestment in R&D and services, funds debt reduction or strategic M&A, and underpins financial flexibility over coming quarters.

Return to Profitability

Re-establishing positive net income and materially higher EBIT in 2025 demonstrates operational recovery and margin restoration versus recent losses. A sustained earnings base improves ability to fund recurring service programs, pricing initiatives and long-term product investments.

Manageable Leverage

Leverage at moderate levels (debt-to-equity ~0.62–0.64) provides balance between using debt for growth and retaining creditor flexibility. This structural profile allows Philips to invest in capital equipment, services and software while keeping refinancing and covenant risk contained if earnings remain stable.

Negative Factors

Earnings and Cash Volatility

Material swings in earnings and cash flow across 2022–2024 reduce confidence in sustainable margins and planning. Persistent volatility makes multi-quarter forecasting and investment decisions harder, raising the premium on consistent execution to convert recent improvements into lasting performance.

Balance-Sheet Contraction & Rising Debt

Declining equity and rising debt in 2025 indicate a shrinking balance-sheet cushion and higher leverage risk if headwinds reappear. Reduced assets and equity limit flexibility for large capital investments, and place more importance on steady cash generation to service debt and avoid further balance-sheet erosion.

Revenue Cyclicality and Long Sales Cycles

Dependence on hospital capital spending and long sales/install cycles creates lumpy, timing-sensitive revenue streams and slower visibility into demand. This structural characteristic constrains topline predictability and slows conversion of product innovation into steady recurring revenue.

Koninklijke Philips N.V. Business Overview & Revenue Model

Company Description

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes Money

Philips primarily makes money by selling health-technology equipment, associated consumables, software, and services to healthcare providers and, in certain categories, to consumers. Key revenue streams typically include: (1) hardware and system sales—large capital equipment and devices such as diagnostic imaging systems, ultrasound platforms, image-guided therapy systems, and patient monitoring equipment sold to hospitals and clinics; (2) recurring revenue tied to the installed base—service contracts (maintenance, repairs, upgrades), managed services, and parts that support deployed equipment over multi-year lifecycles; (3) software and informatics—clinical and operational software offerings and related implementation/support services that can be sold as licenses and/or subscription-based arrangements (specific contract structures vary by product and customer); and (4) consumables and accessories—items used with certain systems and therapies that generate repeat purchases. Revenue is influenced by hospital capital spending cycles, long sales and installation timelines for complex systems, and the size and retention of Philips’ installed base that drives service and upgrade demand. Specific material partnerships or revenue-share arrangements: null.

Koninklijke Philips N.V. Financial Statement Overview

Summary

Financials are improving, driven by a return to profitability in 2025 (net income €0.9B; EBIT €1.65B) and strong 2025 free cash flow (~€0.90B, +242%). Offsetting this, results were volatile across 2022–2024 with losses and cash-flow variability, and the balance sheet shows some weakening (equity down since 2022 and total debt rising in 2025).

Income Statement

Profitability has clearly improved after the 2022–2024 loss period: 2025 returned to positive earnings (net income €0.9B vs. a loss in 2024) and operating profit strengthened materially (EBIT €1.65B vs. €0.53B in 2024). Revenue has been relatively stable around ~€18B for several years, with 2025 showing a strong rebound in growth (+29.8%) after slight contraction in 2024. Offsetting this, the last four-year pattern shows meaningful volatility (deep 2022 operating loss, continued losses in 2023–2024), which lowers confidence in the consistency of margins and earnings power.

Balance Sheet

Leverage appears manageable for the business: debt-to-equity was ~0.62–0.64 in 2023–2024, indicating moderate balance-sheet risk rather than aggressive leverage. However, equity has trended down from 2022 to 2025 (from ~€13.25B to ~€10.96B), and total debt increased in 2025 (to ~€8.09B). Total assets have also declined over time (from ~€30.7B in 2022 to ~€26.9B in 2025), suggesting balance-sheet contraction and/or asset write-down pressure, which is a key watch item.

Cash Flow

Cash generation is a relative strength. Free cash flow was positive in every year except 2022, and operating cash flow has been consistently positive again since 2023. 2025 delivered strong free-cash-flow growth (+242%) with free cash flow of ~€0.90B, supporting financial flexibility. The main weakness is variability: 2022 saw negative operating and free cash flow, and free cash flow declined in 2024 versus 2023, highlighting that cash conversion can swing meaningfully year to year.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	17.83B	18.02B	18.17B	17.83B	17.16B
Gross Profit	8.06B	7.77B	7.45B	7.19B	7.17B
EBITDA	2.77B	1.85B	1.04B	-280.00M	1.73B
Net Income	896.00M	-702.00M	-466.00M	-1.61B	3.32B
Balance Sheet
Total Assets	26.94B	28.98B	29.41B	30.69B	30.96B
Cash, Cash Equivalents and Short-Term Investments	2.79B	2.40B	1.87B	1.18B	2.31B
Total Debt	8.09B	7.49B	7.69B	8.20B	6.98B
Total Liabilities	15.96B	16.93B	17.34B	17.41B	16.49B
Stockholders Equity	10.96B	12.01B	12.03B	13.25B	14.44B
Cash Flow
Free Cash Flow	903.00M	893.00M	1.49B	-979.00M	866.00M
Operating Cash Flow	1.17B	1.57B	2.14B	-173.00M	1.63B
Investing Cash Flow	-747.00M	-573.00M	-636.00M	-1.49B	-3.67B
Financing Cash Flow	107.00M	-496.00M	-848.00M	500.00M	-2.35B

Koninklijke Philips N.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 22.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:PHIA, the sentiment is Negative. The current price of 22.83 is below the 20-day moving average (MA) of 25.27, below the 50-day MA of 25.31, and below the 200-day MA of 23.59, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 28.63 is Positive, neither overbought nor oversold. The STOCH value of 4.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:PHIA.

Koninklijke Philips N.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLPG	71 Outperform	€1.82B	5.75	-16.72%	―	―	―
PHIA	64 Neutral	€21.70B	24.59	-7.02%	3.73%	-0.81%	-54.90%
PHARM	56 Neutral	€955.31M	408.57	0.87%	―	24.19%	99.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%